MiMedx Guidance Slashed, Stock Downgraded on Reimbursement Wocs

What happened

MiMedx Group's 2026 revenue guidance was slashed to $260–$290 million from previous $340–$360 million, following a 33% Q1 revenue drop. Wound care sales plummeted 60%, highlighting the severe impact of Medicare's $127.14/cm² skin-substitute cap. The DeepValue Master Report's base case ($340–$360M) now appears unattainable, as realized performance falls even below its bear case ($330M). A DCF model values MDXG at $3.93, only ~6% above the current price, confirming limited upside. The stock has been downgraded from Buy to Hold as the reimbursement reset proves more damaging than initially feared.

Implication

Investors should recognize that the reimbursement headwind is deeper and more prolonged than anticipated. The company's guided revenue of $260–$290M implies a structural decline in wound care that may not be offset by surgical growth. Cash burn risks increase if sales fail to recover, and the $100M buyback authorization offers no support amid falling earnings. Wait for evidence of sequential stabilization in wound sales and margin recovery before reconsidering a position.

Thesis delta

The thesis shifts from a manageably uncertain transition to a confirmed structural downturn. The base case ($340–$360M) is invalidated, and even the bear case ($330M) is too optimistic. The new guidance of $260–$290M suggests a deeper, potentially permanent impairment of wound care revenue, with upside limited to ~6% from DCF value. The wait-and-see approach must be more cautious, as the stock now trades near its revised intrinsic value with no catalyst for rebound.